10-KPeriod: FY2011

ELI LILLY & Co Annual Report, Year Ended Dec 31, 2011

Filed February 24, 2012For Securities:LLY

Summary

Eli Lilly and Company's 2011 10-K filing highlights a year of revenue growth driven by key products like Cymbalta and insulin, alongside a notable increase in its Animal Health segment. However, this growth was offset by decreased net income, primarily due to the impact of U.S. healthcare reform, increased operating expenses, and charges related to restructuring and collaborations. The company is facing significant patent expirations for major products like Zyprexa and Cymbalta, which are expected to materially impact future revenues. Lilly is actively managing these challenges by investing heavily in its late-stage pipeline, exploring strategic collaborations, and focusing on emerging markets and its animal health business to drive future growth. The filing also details ongoing legal and regulatory matters, including patent litigation and investigations into marketing practices, which represent potential risks. The company's financial condition remains solid with substantial cash reserves and manageable debt, although it is largely self-insured for product liability claims. Investors should closely monitor the impact of patent expirations, the success of new product development, and the evolving regulatory landscape.

Financial Highlights

54 data points
Beta

Revenue

$24.29B

79.1% Gross Margin

Net Income

$4.35B

17.9% Net Margin

EPS (Diluted)

$3.90

Total Assets

$33.66B

Cash & Equivalents

$5.92B

Free Cash Flow

$7.23B

Financial Statements
Beta
Revenue$24.29B
Cost of Revenue$5.07B
Gross Profit$19.22B
R&D Expenses$5.02B
SG&A Expenses$7.88B
Interest Expense$186.00M
Net Income$4.35B
EPS (Basic)$3.90
EPS (Diluted)$3.90
Shares Outstanding (Basic)1.11B
Shares Outstanding (Diluted)1.11B

Key Highlights

  • 1Revenue increased by 5% to $24.29 billion in 2011, driven by Cymbalta, insulin products, animal health, Alimta, Effient, and Cialis.
  • 2Net income decreased by 14% to $4.35 billion, or $3.90 per share, due to increased operating expenses and specific charges, including $408.8 million related to U.S. healthcare reform.
  • 3Zyprexa revenue declined by 8% due to patent exclusivity loss in October 2011, with an expected further decline of over $3 billion in 2012.
  • 4The company reported robust growth in its Animal Health segment, with sales increasing by 21% to $1.68 billion.
  • 5R&D expenses increased by 3% to $5.02 billion, reflecting continued investment in a pipeline of approximately 65 potential new drugs.
  • 6Key patent expirations are looming for major products such as Cymbalta (2013) and Humalog (2013), posing a significant risk to future revenue.
  • 7The company is actively involved in patent litigation concerning Alimta and Strattera, with potential material impacts on future results.
  • 8Eli Lilly reported a strong financial position with $6.90 billion in cash, cash equivalents, and short-term investments at year-end 2011.

Frequently Asked Questions

In 2011, Eli Lilly's revenue was primarily driven by the collective growth of Cymbalta, its insulin products (Humalog and Humulin), animal health products, Alimta, Effient, and Cialis. These products showed strong performance, contributing to overall revenue growth.

The most significant risk highlighted is the impending loss of patent exclusivity for several major products. Zyprexa has already lost exclusivity in the U.S. and Europe, with expected significant revenue declines. Cymbalta and Humalog are set to lose U.S. patent protection in 2013, and Evista in 2014. The loss of exclusivity typically leads to a rapid and severe decline in sales due to generic competition.

Eli Lilly is heavily investing in its research and development pipeline, with approximately 65 drug candidates in human testing. The company is also pursuing strategic collaborations, such as the diabetes collaboration with Boehringer Ingelheim, and is focusing on growing its Animal Health business (Elanco) and expanding in emerging markets and Japan. These efforts are aimed at offsetting the impact of patent expirations and driving future revenue streams.

Eli Lilly maintained a solid financial position in 2011, with cash, cash equivalents, and short-term investments totaling $6.90 billion. The company generated strong operating cash flow and had total debt of $6.99 billion, with a stable outlook from credit rating agencies. Dividends have been paid consistently, indicating financial stability, though the company is largely self-insured for product liability claims.